SABCS 2019

Oral Paclitaxel With Encequidar Deemed Effective in Metastatic Breast Cancer, but Toxicity Concerns Emerge

Patients who received oral paclitaxel with encequidar had lower rates of neuropathy, but higher rates of neutropenia, anemia, and gastrointestinal adverse events.

Tumor Biopsy Does Not Improve Predictive Value of Trimodality Imaging

Image-guided core-needle biopsy did not improve the predictive value of trimodality imaging after neoadjuvant therapy for patients with operable breast cancer.

Estrogen Alone Appears to Lower Breast Cancer Risk and Death Long Term in Patient Subgroup

Estrogen alone and estrogen plus progestin appeared to have “opposite effects” on risk of breast cancer and death among postmenopausal women.

Residual Cancer Burden Is Prognostic Across Breast Cancer Subtypes in the Long Term After Neoadjuvant Therapy

A multicenter pooled analysis found that residual cancer burden index after neoadjuvant therapy was prognostic in the long-term across 4 breast cancer subtypes.

Detection of ctDNA Linked to Worse Clinical Outcomes in TNBC

The quantitative burden of ctDNA was also associated with significantly worse distant disease-free survival.

Study Finds Many Breast Cancer Drugs Lack Substantial Clinical Benefit

Many breast cancer drugs approved in the United States may lack substantial clinical benefit, particularly in the palliative setting.

Maintenance Durvalumab Shows Activity in Certain Breast Cancer Subgroups

Exploratory subgroup analyses suggest patients with triple-negative breast cancer or PDL1-positive tumors may benefit from maintenance durvalumab.

Subcutaneous Pertuzumab and Trastuzumab Offers Convenience to Patients With HER2-Positive Breast Cancer

A fixed-dose combination of subcutaneous pertuzumab and trastuzumab was found to be noninferior for patients with HER2-positive breast cancer.

Adjuvant Paclitaxel and Trastuzumab Offer Same Survival Outcomes in HER2-Positive Early Breast Cancer

Compared to historical controls, adjuvant paclitaxel and trastuzumab seems to provide the same benefit for patients with low-risk, HER2-positive early breast cancer.

Pathologists in the Real World May Be Misinterpreting Immune-Cell Scores in Patients With Triple-Negative Breast Cancer

Researchers warn that pathologists may be assigning the wrong immune cell score with PD-L1 assays to patients, leading to inappropriate treatment recommendations.

CD16A-F Carriers Appear to Benefit Most From Margetuximab and Chemo

Margetuximab plus chemotherapy continues to improve outcomes in patients with HER2-positive metastatic breast cancer, particularly among CD16A-F carriers.

APHINITY Update: Pertuzumab Found to Lower Risk of Relapse in the Long Term, but Survival Benefit Is Unclear

Patients at high risk of recurrence had an invasive disease-free survival benefit from pertuzumab in the long term, but the survival benefit is unclear.

Endocrine Therapy With Palbociclib: No PFS Advantage in Metastatic Breast Cancer

Endocrine therapy with palbociclib did not offer a progression-free survival advantage over capecitabine in patients with metastatic breast cancer.

Prediction Models May Help Forecast Response, Adverse Events With CDKI Therapy

Prediction models helped forecast how patients with metastatic breast cancer would respond to CDKI therapy and the adverse events they may develop.

Breast Cancer Risk Identified for Predisposition Genes in General Population

In the general population, BRCA1, BRCA2, PALB2, and ATM mutations were linked to a significant increased risk of breast cancer.

Adding Tucatinib Led to Survival Gain in Metastatic Breast Cancer

Adding tucatinib to capecitabine and trastuzumab improved survival for patients with metastatic HER2-positive breast cancer, including those with brain metastases.

The 2019 San Antonio Breast Cancer Symposium: What to Expect

Talks from the meeting will offer insights on the prevention and diagnosis of disease, and will also compare novel therapeutic interventions with older standards of care.